News

The patent, entitled Chemically Modified Ligase Cofactors, Donors, and Acceptors, is directed toward the use of modified ligation components to improve fidelity in nucleic acid ligation. The research

The new platform will be based on Akrivis Technologies’ proprietary Z-TECT technology that targets and detects unusually low levels of proteins and molecular targets and Leti’s Lipidot nanovector

Under the deal, Cipher has granted Andrómaco the exclusive right to market, sell and distribute its isotretinoin capsules in the country. After securing regulatory approval, it is expected

Under the deal, the company will be working with nanoRANCH’s Dan Dimitrijevich to create new treatment delivery methods using a combination of nanoRANCH technology and CRYO’s clinically processed

Cellectis said that its CAR-T technology offers an allogeneic approach in developing CAR-T therapies that are distinct from other autologous approaches. As part of the deal, Pfizer will

VX-787 is an influenza A-specific, oral polymerase inhibitor designed to directly inhibit replication of the influenza A virus, including recent H1 and H5 influenza strains, based on in-vitro

Under the deal, Medison will market Glybera, uniQure’s gene therapy product for the treatment of lipoprotein lipase deficiency (LPLD), in Israel and the Palestinian Authority. Medison will also

ProMetic’s PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested. The objectives of this

The patents, which expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of